A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy
- PMID: 2593864
- DOI: 10.1016/0378-5122(89)90212-0
A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy
Abstract
Previous studies have shown that continuous oral oestrogen-progestogen therapy, which is a relatively new treatment regimen, does not induce endometrial hyperstimulation. However, bleeding disturbances are common during the early months of therapy and in the present study we used both conventional methods of statistical analysis and a stochastic model to describe the bleeding patterns. Four groups of 15 post-menopausal women were given different oral formulations continuously for 1 yr. The oestrogen component in all cases was 2 mg 17 beta-estradiol. The progestogen used was norethisterone acetate at a dose of either 1 mg or 0.5 mg (Groups A and B) or megestrol acetate at a dose of either 5 mg and 2.5 mg (Groups C and D). Each woman kept a daily record of all bleeding episodes, 80% of which occurred during the first 4 mth of therapy. Analysis of variance showed that the high doses of the two progestogens were associated with less spotting and menstrual-like bleeding than the low doses. Stochastic analysis of the bleeding data confirmed that women on the high progestogen doses experienced fewer bleeding episodes than those on the low doses. It also showed that women receiving the high progestogen doses who weighed under 67 kg or had had their last menstruation over 5 yr previously bled less than the other women in the high-dose groups.
Similar articles
-
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.Maturitas. 2002 Dec 10;43(4):265-75. doi: 10.1016/s0378-5122(02)00203-7. Maturitas. 2002. PMID: 12468135 Clinical Trial.
-
A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women.Gynecol Endocrinol. 2005 Aug;21(2):82-9. doi: 10.1080/09513590500168472. Gynecol Endocrinol. 2005. PMID: 16294460 Clinical Trial.
-
Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.Int J Fertil Womens Med. 1997;42 Suppl 2:376-87. Int J Fertil Womens Med. 1997. PMID: 9397385 Clinical Trial.
-
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.Adv Ther. 2008 Jun;25(6):525-51. doi: 10.1007/s12325-008-0070-6. Adv Ther. 2008. PMID: 18568306 Review.
-
Pharmacodynamic effects of once-a-month combined injectable contraceptives.Contraception. 1994 Apr;49(4):361-85. doi: 10.1016/0010-7824(94)90033-7. Contraception. 1994. PMID: 8013220 Review.
Cited by
-
Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD000402. doi: 10.1002/14651858.CD000402.pub4. Cochrane Database Syst Rev. 2012. PMID: 22895916 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical